

Datasheet for ABIN6952526

SARS-CoV-2 IgM Antibody ELISA Kit

5 Publications



[Go to Product page](#)

Overview

Quantity:	96 tests
Target:	SARS-CoV-2 IgM Antibody
Reactivity:	Human, SARS Coronavirus-2 (SARS-CoV-2)
Method Type:	Sandwich ELISA
Application:	ELISA

Product Details

Purpose:	Enzyme Linked Immunosorbent Assays (ELISA) for the qualitative detection of the COVID-19 IgM in human serum.
Sample Type:	Serum
Analytical Method:	Qualitative
Detection Method:	Colorimetric
Characteristics:	gM is first immunoglobulin to be produced in response to an antigen and will be primarily detectable during the early onset of the disease. IgM antibodies begin to show positive after 3-5 days of onset.
Components:	<ul style="list-style-type: none">• COVID-19 IgM coated Microplate• COVID-19 IgM Sample Diluent• HRP labeled COVID-19 Antigen• ELISA Wash Concentrate• ELISA HRP Substrate• ELISA Stop Solution• COVID-19 IgM Negative Control• COVID-19 IgM Positive Control

Product Details

Material not included:	<ul style="list-style-type: none">• Precision single channel pipettes capable of delivering 10 µL, 25 µL, 100 µL, and 1000 µL, etc.• Repeating dispenser suitable for delivering 100 µL.• Disposable pipette tips suitable for above volume dispensing.• Disposable 12 x 75 mm or 13 x 100 glass tubes.• Disposable plastic 1000 mL bottle with caps.• Aluminum foil.• Deionized or distilled water.• Plastic microtiter well cover or polyethylene film.• ELISA multichannel wash bottle or automatic (semi-automatic) washing system.• Spectrophotometric microplate reader capable of reading absorbance at 450 nm.
------------------------	---

Target Details

Target:	SARS-CoV-2 IgM Antibody
---------	-------------------------

Target Type:	Antibody
--------------	----------

Application Details

Application Notes:	National Health Commission of the People's Republic of China states that IgM antibodies begin to show positive after 3-5 days of onset of COVID-19
--------------------	--

Plate:	Pre-coated
--------	------------

Protocol:	<p>Assay controls and samples are added to the microtiter wells of a microplate that was coated with a anti-human IgM specific antibody. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (H labeled recombinant COVID-19 antigen is added to each well. After an incubation period, an immunocomplex of "Anti-IgM antibody COVID-19 IgM antibody - HRP labeled COVID-19 antigen" is formed if there is novel coronavirus IgM antibody present in the tested materials. The unbound tracer antigen is removed by the subsequent washing step. HRP-labeled COVID-19 antigen tracer bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antigen bound to the coronavirus IgM on the wall of the microtiter well is proportional to the amount of the coronavirus IgM antibody level in the tested materials.</p>
-----------	---

Restrictions:	For Research Use only
---------------	-----------------------

Handling

Storage:	4 °C
----------	------

Handling

Storage Comment: This test kit must be stored at 2 - 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

Publications

Product cited in: Egger, Bundschuh, Wiesinger, Gabriel, Clodi, Mueller, Dieplinger: "Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma." in: **Clinica chimica acta; international journal of clinical chemistry**, Vol. 509, pp. 18-21, (2020) ([PubMed](#)).

Bundschuh, Egger, Wiesinger, Gabriel, Clodi, Mueller, Dieplinger: "Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma." in: **Clinica chimica acta; international journal of clinical chemistry**, Vol. 509, pp. 79-82, (2020) ([PubMed](#)).

Hubiche, Le Duff, Chiaverini, Giordanengo, Passeron: "Negative SARS-CoV-2 PCR in patients with chilblain-like lesions." in: **The Lancet. Infectious diseases**, (2020) ([PubMed](#)).

Charlton, Kanji, Johal, Bailey, Plitt, MacDonald, Kunst, Buss, Burnes, Fonseca, Berenger, Schnabl, Hu, Stokes, Zelyas, Tipples: "Evaluation of six commercial mid to high volume antibody and six point of care lateral flow assays for detection of SARS-CoV-2 antibodies." in: **Journal of clinical microbiology**, (2020) ([PubMed](#)).

Baron, Risch, Weber, Thiel, Grossmann, Wohlwend, Lung, Hillmann, Ritzler, Bigler, Egli, Ferrara, Bodmer, Imperiali, Heer, Renz, Flatz, Kohler, Vernazza, Kahlert, Paprotny, Risch: "Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study." in: **Clinical chemistry and laboratory medicine**, (2020) ([PubMed](#)).